Aegis sees big upside for NeoStem on AMR-001 potential

Moving sharply higher on the day are shares of NeoStem (NBS +11.7%).

Helping the cause is Aegis' Ram Selvaraju who is "enthused about the completion of enrollment [in PreSERVE], given the lengthy period of time that this trial has taken to accrue the requisite number of patients."

The analyst remains "confident that the AMR-001 Phase 2 study has a high likelihood of success."

Price target hiked to $23 (from $21). For what it's worth, that represents upside of 240% from Tuesday's close.

Comments (5)
  • oliver22
    , contributor
    Comments (13) | Send Message
    2 Jan 2014, 01:02 PM Reply Like
  • smokess
    , contributor
    Comments (43) | Send Message
    Great start to the new year!
    2 Jan 2014, 01:14 PM Reply Like
  • Heefcleeve
    , contributor
    Comments (42) | Send Message
    YES! Got in last week. Nice start into 2014.
    2 Jan 2014, 02:06 PM Reply Like
  • skywola
    , contributor
    Comments (172) | Send Message
    Been long on this stock for months . . . . . good to see some appreciation.
    2 Jan 2014, 09:19 PM Reply Like
  • toosmarttofail
    , contributor
    Comments (699) | Send Message
    Didn't AEGIS underwrite its dilution the last few times?


    NBS is a "jumping bean" and they're another synthetic-stem company. Embryonic stemcells are the state of the art; the synths are going to have issues long-term.


    The available-shares on this stock are still the same as pre-split, which means you could see msasive dilution going forward. I'd be careful here. If you can get options or warrants try that bet for less money and throw the rest into ACTC.
    3 Jan 2014, 12:23 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs